RT Journal Article
SR Electronic
T1 Saliva-based detection of COVID-19 infection in a real-world setting using reagent-free Raman spectroscopy and machine learning
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.21.21262619
DO 10.1101/2021.09.21.21262619
A1 Ember, Katherine
A1 Daoust, François
A1 Mahfoud, Myriam
A1 Dallaire, Frédérick
A1 Zamani, Esmat
A1 Tran, Trang
A1 Plante, Arthur
A1 Diop, Mame-Kany
A1 Nguyen, Tien
A1 St-Georges-Robillard, Amélie
A1 Ksantini, Nassim
A1 Lanthier, Julie
A1 Filiatrault, Antoine
A1 Sheehy, Guillaume
A1 Quach, Caroline
A1 Trudel, Dominique
A1 Leblond, Frédéric
YR 2021
UL http://medrxiv.org/content/early/2021/09/23/2021.09.21.21262619.abstract
AB Significance The primary method of COVID-19 detection is reverse transcription polymerase chain reaction (RT-PCR) testing. PCR test sensitivity may decrease as more variants of concern arise.Aim We aimed to develop a reagent-free way to detect COVID-19 in a real-world setting with minimal constraints on sample acquisition.Approach We present a workflow for collecting, preparing and imaging dried saliva supernatant droplets using a non-invasive, label-free technique – Raman spectroscopy – to detect changes in the molecular profile of saliva associated with COVID-19 infection.Results Using machine learning and droplet segmentation, amongst all confounding factors, we discriminated between COVID-positive and negative individuals yielding receiver operating coefficient (ROC) curves with an area under curve (AUC) of 0.8 in both males (79% sensitivity, 75% specificity) and females (84% sensitivity, 64% specificity). Taking the sex of the saliva donor into account increased the AUC by 5%.Conclusion These findings may pave the way for new rapid Raman spectroscopic screening tools for COVID-19 and other infectious diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors acknowledge funding from the Canada First Research Excellence Fund (TransMedTech Institute, IVADO), the Natural Sciences and Engineering Research Council of Canada (Alliance and Discovery grant programs) and the Canada Foundation for Innovation (Exceptional Opportunities Fund program). The first author was funded by TransMedTech Institute through a postdoctoral fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Work was carried out in accordance with ethical guidelines from the Centre Hospitalier de l'Université de Montréal (CHUM) Research Ethics Board (project number: 20.133).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request from the authors.Abbreviations:KEKatherine EmberFD1François DaoustMMMyriam MahfoudFD2Frédérick DallaireEZEsmat ZamaniTTTrang TranAPArthur PlanteMKDMame-Kany DiopTNTien NguyenASAmélie St-Georges-RobillardNKNassim KsantiniJLJulie LanthierAFAntoine FiliatraultGSGuillaume SheehyCQCaroline Quach,DTDominique TrudelFLFrédéric Leblond